Global Antiviral Drugs Market By Drug Class (Nucleoside & Nucleotide Analogues, Protease Inhibitors, Integrase Inhibitors, Neuraminidase Inhibitors, Reverse Transcriptase Inhibitors, Fusion & Entry Inhibitors, Polymerase Inhibitors, and Others), By Indication (Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C, Influenza, Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Respiratory Syncytial Virus (RSV), COVID-19, and Others), By Route of Administration (Oral, Injectable, Topical, and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Drug Type (Branded Drugs and Generic Drugs), By Age Group (Pediatric, Adult, and Geriatric), By Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026–2035
Report Overview Global Antiviral Drugs Market size is expected to be worth around US$ 98.0 Billion by 2035 from US$ 68.2 Billion in 2025, growing at a CAGR of 3.7% during the forecas...
